Mixed tumor, polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma: pathogenic implications and differential diagnosis by Ki-67 (MIB1), BCL2, and S-100 immunohistochemistry.
Selective immunohistochemical comparison of polymorphous low-grade adenocarcinoma and adenoid cystic carcinoma.
Hierarchical cluster analysis of myoepithelial/basal cell markers in adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma. Mod Pathol.
The Differentiation of Adenoid Cystic Carcinoma, Polymorphous Low-Grade Adenocarcinoma, and Pleomorphic Adenoma c-KIT Calponin/SMA/SMMHC CK7 MIB-1 AdCC + + +, luminal cells >10% PLGA - or + - or +, focal +, all cells <5% PA - or + + +, luminal cells <5% Myb PLGA1 GFAP AdCC + or - - - PLGA - - - PA - + + Abbreviations: AdCC, adenoid cystic carcinoma; CK, cytokeratin; GFAP, glial fibrillary acidic protein; PA, pleomorphic adenoma; PLGA, polymorphous low-grade adenocarcinoma; SMA, smooth muscle actin; SMMHC, smooth muscle myosin heavy chain.
Although coexpression of both mammaglobin and S100 protein is characteristic of mammary analogue secretory carcinoma, polymorphous low-grade adenocarcinomas (60%) and adenoid cystic carcinomas (13.3%) showed significant coexpression of both markers without evidence of ETV6-NTRK3 fusion.
The differential diagnoses that we considered included polymorphous low-grade adenocarcinoma, primary or metastatic papillary thyroid carcinoma, and adenoid cystic carcinoma.
Polymorphous low-grade adenocarcinoma: A case report with ultrastructural findings.
Polymorphous low-grade adenocarcinoma of minor salivary glands: A study of 17 cases with emphasis on cell differentiation.
Among them are polymorphous low-grade adenocarcinomas, lobular carcinomas, terminal duct carcinomas, and low-grade papillary adenocarcinomas.